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1488ABSTRACT
Background. The diagnostic criteria of antibody-mediated rejection (ABMR) has been
significantly changed since Banff 2013. The most important revision was adopting
microvascular inflammation (MVI) as immunopathologic evidence for ABMR even in
C4d-negative cases. In this study, we retrospectively reviewed previous allograft biopsy
results and evaluated the impact of this change.
Methods. We reviewed results of 536 renal allograft biopsies at Severance Hospital
during 2011 to 2013, which were diagnosed according to the Banff 2009 criteria. All biopsy
results were reassessed according to the Banff 2017 criteria.
Results. According to the Banff 2009 criteria, antibody-mediated changes were observed
in 48 cases out of the 536 allograft biopsies (9.0%). According to the Banff 2017 criteria, 28
additional cases (5.2%) were reclassified as antibody-mediated changes. Twenty-six of
these cases were C4d-negative ABMR. The most frequent diagnostic finding in these
cases was MVI comprising glomerulitis and peritubular capillaritis. Donor-specific
antibodies were investigated in 14 of these cases, which revealed positive results in 12 cases.
Conclusion. The incidence rate of ABMR has increased after the recent revision of the
Banff criteria. The MVI in C4d-negative ABMR cases is the major cause for this increase.H.S. Jeong and D.G. Kim contributed equally to this article.
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(ABMR). From the earliest attempt to incorporate the diag-
nostic criteria of ABMR into the Banff schema [1], linear
peritubular capillary staining of C4d has been emphasized to
be the most important evidence for antibody-mediated injury.
The Banff 2013 classification made a major revision in the
diagnosis procedure of ABMR by including C4d-negative
ABMR criteria [2]. According to the most recent Banff clas-
sification,C4dpositivity still remains important; however,C4d-
negative ABMR can be diagnosed if patients have significant
glomerulitis and peritubular capillaritis [3]. In this study, we
retrospectively evaluated the clinical significance of the new
diagnostic criteria of ABMR by reclassifying past cases.
METHODS
From 2011 to 2013, a total of 536 medical records of allograft biopsy
after renal transplant were retrieved through an electronic medical
chart maintained by the Department of Pathology and Department9
rg/10.1016/j.transproceed.2019.03.012of Transplant Surgery at Severance Hospital, Yonsei University
Health System. Renal allograft biopsy samples were processed using
light, immunofluorescent, and electron microscopy at the time of
biopsy, as described elsewhere [4]. All the biopsy results that were
initially classified according to the Banff 2009 criteria [5] were
reassessed according to the Banff 2017 criteria [3]. The number of
cases categorized into antibody-mediated changes were counted,
and the initial (Banff 2009) and reassessed (Banff 2017) diagnoses
were compared. Patient data, especially the status of serumª 2019 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1. Cases Originally Diagnosed as Antibody-Mediated
Changes by the Banff 2009 Criteria
Age at transplant, mean (SD), y 42.6 (12.0)
Male sex, No. (%) 24 (50)
Original disease
No pretransplant biopsy, No. (%) 34 (-70.8)
Hypertension 7 (14.6)
Diabetic nephropathy 3 (6.3)
IgA nephropathy 4 (8.3)
Systemic lupus erythematosus 1 (2.1)
Polycystic kidney disease 1 (2.1)
Predialysis duration, mean (SD), mo 32.6 (51.2)
Deceased donor, No. (%) 7 (14.6)
Living donor relation:
1st/2nd/unrelated, No. (%)
17 (35.4)/2 (4.2)/22 (45.8)
Retransplant recipients 3 (6.3)
Pretransplant PRA I > 5% 10 (20.8)
Pretransplant PRA II > 5% 10 (20.8)
HLA mismatch, No. (%), 1/2/3 10/45 (22.2)/9/45
(20.0)/22/45 (48.9)
Cross-match positive transplant 6 (12.5)
ABO-incompatible transplant 5 (10.4)
n ¼ 48 for all data except HLA mismatch where n ¼ 45.
Abbreviation: PRA, panel-reactive antibody.
BANFF CRITERIA AND ANTIBODY-MEDIATED REJECTION 1489donor-specific antibodies (DSAs), were collected whenever possible.
Donor-specific antibody was examined using Luminex bead-based
single-antigen assay (LABScreen SAB Class I and Class II; One
Lambda, Canoga Park, Calif, United States). The presence of each
type of anti-human leukocyte antigen (HLA) DSA (anti-HLA-A, -B,
-DR, and -DQ) was determined and recorded as positive when the
mean fluorescence intensity was >1000. This study was approved by
the Institutional Review Board of Severance Hospital.RESULTS
The Banff 2009 criteria classified antibody-mediated
changes into the following: 1. C4d deposition without
morphologic evidence of active rejection, 2. acute ABMR,
and 3. chronic active ABMR. According to these criteria, 32
cases had histologic features of acute ABMR (6.0% of 536
total allograft biopsy results), and 16 cases (3.0%) had those
of chronic active ABMR. The Banff 2017 classification,
which is the most recent version of the revised criteria of
ABMR, classifies antibody-mediated changes into 1. active
ABMR, 2. chronic active ABMR, and 3. C4d staining
without an evidence of rejection. After applying these
criteria, the diagnosis of the 48 abovementioned cases
remained unchanged (demographic data of these cases are
summarized in Table 1); however, 28 cases (5.2%) had to beTable 2. Cases Newly Diagnosed as Antibody-Media
Initial Diagnosis (Banff 2009) Rev
No rejection or suspicious for rejection
Acute TCMR Acti
Chronic TCMR Activ
TG with negative C4d
TG with negative C4d þ Acute TCMR Chronic
Abbreviations: ABMR, antibody-mediated rejection; TCMR, T-cell-mediated rejectireclassified as having histologic features of
antibody-mediated changes. Among the latter set of cases,
21 exhibited features of active ABMR, and 12 of these cases
additionally exhibited acute T-cell-mediated rejection
(TCMR) while 1 exhibited chronic TCMR. The remaining 7
cases exhibited features of chronic active ABMR, of which 1
exhibited a combined feature of acute TCMR. The initial
diagnoses and their reassessments according to the Banff
2009 and 2017 criteria, respectively, are summarized in
Table 2. Therefore, the total number of cases that exhibited
histologic features of antibody-mediated changes increased
from 48 (9.0%) to 76 (14.2%) after the revision of
diagnostic criteria.
Most of the newly diagnosed ABMR cases were
C4d-negative ABMR (26 of 28 cases, 92.9%). These cases
satisfied the diagnostic criteria of the Banff 2017 classifica-
tion by showing more than moderate microvascular
inflammation (MVI) comprising glomerulitis and peri-
tubular capillaritis (Table 3). All 7 cases having features of
chronic active ABMR showed a duplication of glomerular
basement membranes.
Donor-specific antibody was checked for 14 newly diag-
nosed cases, which was found to be positive in 12 (85.7%)
cases. In 9 patients, DSA was checked at the time of renal
biopsy (within 1 month) and all these patients showed
positive results.
DISCUSSION
C4d positivity in peritubular capillaries has been considered
the criterion standard to distinguish antibody-mediated
injury in allograft kidneys. The Banff 2009 criteria listed the
histologic features of ABMR such as acute tubular injury,
capillaritis, glomerulitis, and transmural arteritis; however,
C4d positivity was considered as a prerequisite for these
features [5]. Subsequently, data showed that MVI is more
closely associated with DSA and has a superior predictability
for patient outcome than C4d positivity [6,7]. Based on these
data, theBanff 2013 extensively revised the diagnostic criteria
of ABMR, and the Banff 2017 further made some modifi-
cations. Currently, 3 categories of evidence are required to
make an ABMR diagnosis. The first one is histologic evi-
dence, encompassing MVI, intimal or transmural arteritis,
acute thrombotic microangiopathy, and acute tubular injury
for activeABMRand transplant glomerulopathy, peritubular
basement membrane multilayering, and arterial intimal
fibrosis for chronic active ABMR. The second category is the
evidence of current and/or recent interaction of antibodiested Changes by Applying the Banff 2017 Criteria
ised Diagnosis (Banff 2017) Cases, No. (%)
Active ABMR 8 (1.5)
ve ABMR þ Acute TCMR 12 (2.2)
e ABMR þ Chronic TCMR 1 (0.2)
Chronic active ABMR 6 (1.1)
active ABMR þ Acute TCMR 1 (0.2)
on; TG, transplant glomerulopathy.
Table 3. Banff 2017 Diagnostic Criteria of Antibody-Mediated Rejection Found in the Newly Diagnosed Cases
g > 0 and/or
ptc > 0 v > 0
Acute
TMA
Acute
Tubular Injury
C4d
Positivity
Moderate
MVI [g þ ptc]  2 cg > 0 PTCBMML
Arterial Intimal
Fibrosis
Cases, No. (%) 27 (96.4) 0 0 5 (17.9) 2 (7.1) 26 (92.9) 7 (25.0) 5 (17.9) 0
Abbreviations: cg, glomerular double contour score; g, glomerulitis score; MVI, microvascular inflammation; TMA, thrombotic microangiopathy; ptc, peritubular
capillaritis score; PTCBMML, peritubular capillary basement membrane multilayering; v, intimal arteritis score.
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tubular capillary, more than moderate degree of MVI, and
ABMR-associated gene transcript expression. These features
are applicable for both active and chronic active ABMR. The
third category is serologic evidence, in other words, the
presence of DSA [3]. All 3 categories are required to make a
final diagnosis of ABMR, but our study focuses on the first
and second categories.
Our study revealed that the frequency of occurrence of
the histologic features of ABMR (according to the first and
second categories) increased from 9.0% to 14.2% after the
application of new diagnostic criteria. This result suggests
that 5.2% of the ABMR cases could have been under-
diagnosed and treated improperly previously. Although
DSA was not checked for in all these cases, most of the
patients for whom DSA was checked demonstrated positive
results, which thereby supported the above conclusion.
In our cases, the most frequent histologic features that
suggested the possibility of ABMR was more than moderate
degree of MVI. There is an overlap between the histologic
features of TCMR and ABMR [8]. Intimal arteritis was
once considered to be a feature of TCMR, but according to
the current Banff criteria, it can now be considered as a
feature of both TCMR and ABMR [3,5]. Considering that
the patients’ outcome is more seriously affected by ABMR
than TCMR [9], it is very important to distinguish and
properly grade glomerulitis and peritubular capillaritis for
optimal patient management.
A limitation of our study is the lack of DSA data among
some patients and the lack of thorough clinical information
to confirm that the newly diagnosed cases had previouslybeen undertreated. However, our observation clearly
revealed that the revised Banff criteria has a clinical sig-
nificance that should further be followed by a clinicopath-
ologic study.REFERENCES
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